ING Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30.5M | Sell |
337,408
-114,239
| -25% | -$9.57M | 0.15% | 118 |
|
|
2026
Q1 | $36.2M | Buy |
451,647
+120,652
| +36% | +$9.95M | 0.22% | 87 |
|
|
2025
Q4 | $28.2M | Buy |
330,995
+277,697
| +521% | +$22.8M | 0.17% | 110 |
|
|
2025
Q3 | $4.14M | Sell |
53,298
-27,387
| -34% | -$2.14M | 0.02% | 304 |
|
|
2025
Q2 | $6.31M | Sell |
80,685
-131,726
| -62% | -$9.82M | 0.04% | 221 |
|
|
2025
Q1 | $15.4M | Buy |
212,411
+137,081
| +182% | +$9.81M | 0.11% | 127 |
|
|
2024
Q4 | $5.58M | Sell |
75,330
-5,235
| -6% | -$366K | 0.04% | 267 |
|
|
2024
Q3 | $5.32M | Sell |
80,565
-522
| -0.6% | -$37.9K | 0.03% | 282 |
|
|
2024
Q2 | $7.49M | Sell |
81,087
-2,022
| -2% | -$179K | 0.04% | 266 |
|
|
2024
Q1 | $7.94M | Sell |
83,109
-30,423
| -27% | -$2.56M | 0.05% | 264 |
|
|
2023
Q4 | $8.66M | Sell |
113,532
-97,787
| -46% | -$6.8M | 0.07% | 228 |
|
|
2023
Q3 | $14.6M | Buy |
+211,319
| New | +$17M | 0.13% | 144 |
|
|
2023
Q2 | – | Sell |
-105,060
| Closed | -$8.69M | – | 590 |
|
|
2023
Q1 | $8.69M | Sell |
105,060
-66,759
| -39% | -$5.25M | 0.08% | 183 |
|
|
2022
Q4 | $12.8M | Buy |
171,819
+74,655
| +77% | +$5.75M | 0.13% | 135 |
|
|
2022
Q3 | $8.03M | Sell |
97,164
-19,836
| -17% | -$1.91M | 0.13% | 126 |
|
|
2022
Q2 | $11.1M | Buy |
117,000
+17,946
| +18% | +$1.86M | 0.13% | 132 |
|
|
2022
Q1 | $11.7M | Sell |
99,054
-56,432
| -36% | -$6.33M | 0.12% | 138 |
|
|
2021
Q4 | $20.1M | Buy |
155,486
+29,155
| +23% | +$3.4M | 0.18% | 106 |
|
|
2021
Q3 | $14.3M | Buy |
126,331
+75,276
| +147% | +$8.59M | 0.18% | 89 |
|
|
2021
Q2 | $5.29M | Buy |
51,055
+9,706
| +23% | +$915K | 0.08% | 154 |
|
|
2021
Q1 | $3.46M | Buy |
41,349
+10
| +0% | +$845 | 0.07% | 166 |
|
|
2020
Q4 | $3.77M | Buy |
41,339
+27,579
| +200% | +$2.29M | 0.08% | 162 |
|
|
2020
Q3 | $1.1M | Buy |
13,760
+8,519
| +163% | +$665K | 0.05% | 188 |
|
|
2020
Q2 | $362K | Buy |
+5,241
| New | +$372K | 0.02% | 208 |
|
|
2020
Q1 | – | Sell |
-42,918
| Closed | -$3.34M | – | 433 |
|
|
2019
Q4 | $3.34M | Buy |
42,918
+3,978
| +10% | +$311K | 0.1% | 142 |
|
|
2019
Q3 | $2.85M | Sell |
38,940
-39,915
| -51% | -$2.8M | 0.07% | 176 |
|
|
2019
Q2 | $4.86M | Sell |
78,855
-1,080
| -1% | -$65.3K | 0.08% | 160 |
|
|
2019
Q1 | $5.1M | Buy |
+79,935
| New | +$4.56M | 0.11% | 127 |
|
|
2018
Q4 | – | Sell |
-34,440
| Closed | -$2M | – | 743 |
|
|
2018
Q3 | $2M | Buy |
34,440
+27,330
| +384% | +$1.34M | 0.03% | 258 |
|
|
2018
Q2 | $345K | Sell |
7,110
-57,267
| -89% | -$2.67M | 0.01% | 581 |
|
|
2018
Q1 | $2.99M | Buy |
64,377
+30,645
| +91% | +$1.33M | 0.05% | 173 |
|
|
2017
Q4 | $1.27M | Sell |
33,732
-34,983
| -51% | -$1.28M | 0.02% | 292 |
|
|
2017
Q3 | $2.5M | Buy |
68,715
+20,052
| +41% | +$765K | 0.05% | 204 |
|
|
2017
Q2 | $1.92M | Sell |
48,663
-345
| -0.7% | -$12.6K | 0.04% | 223 |
|
|
2017
Q1 | $1.54M | Sell |
49,008
-4,362
| -8% | -$137K | 0.03% | 282 |
|
|
2016
Q4 | $1.67M | Buy |
53,370
+13,272
| +33% | +$430K | 0.03% | 237 |
|
|
2016
Q3 | $1.59M | Buy |
40,098
+33,456
| +504% | +$1.26M | 0.02% | 237 |
|
|
2016
Q2 | $221K | Sell |
6,642
-8,070
| -55% | -$276K | ﹤0.01% | 488 |
|
|
2016
Q1 | $433K | Sell |
14,712
-1,512,393
| -99% | -$41.7M | 0.01% | 394 |
|
|
2015
Q4 | $40.2M | Buy |
1,527,105
+26,685
| +2% | +$693K | 0.24% | 107 |
|
|
2015
Q3 | $35.5M | Buy |
1,500,420
+603,234
| +67% | +$14.6M | 0.25% | 94 |
|
|
2015
Q2 | $21.3M | Sell |
897,186
-145,866
| -14% | -$3.29M | 0.12% | 163 |
|
|
2015
Q1 | $24.8M | Buy |
+1,043,052
| New | +$23.4M | 0.12% | 178 |
|
Other funds holding EW
ING Group's EW Position: Q2 2026 in Review
ING Group reduced its Edwards Lifesciences (EW) stake by 25% in Q2 2026, selling an estimated $9.57M and leaving 337,408 shares worth $30.5M. The position accounts for 0.15% of the portfolio, ranked #118.
ING Group first reported a position in EW in Q1 2015 and has held it in 43 quarters since. The position peaked at $40.2M in Q4 2015. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- ING Group held 337,408 shares of Edwards Lifesciences worth $30.5M as of Q2 2026.
- ING Group sold 114,239 Edwards Lifesciences shares in Q2 2026, an estimated $9.57M.
- Edwards Lifesciences made up 0.15% of ING Group's portfolio in Q2 2026, its #118 holding.
- ING Group first reported a position in Edwards Lifesciences in Q1 2015 and has held it in 43 quarters since.
- ING Group's Edwards Lifesciences position peaked at $40.2M in Q4 2015.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.